Depreciation, Depletion and Amortization of VERTEX PHARMACEUTICALS INC / MA from 31 Mar 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary
VERTEX PHARMACEUTICALS INC / MA quarterly and annual Depreciation, Depletion and Amortization in USD history and change rate from 31 Mar 2010 to 31 Dec 2025.
  • VERTEX PHARMACEUTICALS INC / MA Depreciation, Depletion and Amortization for the quarter ending 31 Dec 2025 was $55,700,000, a 20% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA Depreciation, Depletion and Amortization for the twelve months ending 31 Dec 2025 was $209,800,000, a 1.3% increase year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA annual Depreciation, Depletion and Amortization for 2025 was $209,800,000, a 1.3% increase from 2024.
  • VERTEX PHARMACEUTICALS INC / MA annual Depreciation, Depletion and Amortization for 2024 was $207,200,000, a 14% increase from 2023.
  • VERTEX PHARMACEUTICALS INC / MA annual Depreciation, Depletion and Amortization for 2023 was $181,300,000, a 22% increase from 2022.
Source SEC data
View on sec.gov
Depreciation, Depletion and Amortization, Trailing 12 Months (USD)
Depreciation, Depletion and Amortization, Quarterly (USD)
Depreciation, Depletion and Amortization, YoY Quarterly Change (%)
Depreciation, Depletion and Amortization, Annual (USD)
Depreciation, Depletion and Amortization, YoY Annual Change (%)

VERTEX PHARMACEUTICALS INC / MA Quarterly Depreciation, Depletion and Amortization (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $209,800,000 $55,700,000 +$9,200,000 +20% 01 Oct 2025 31 Dec 2025 10-K 13 Feb 2026 2025 FY
Q3 2025 $200,600,000 $54,000,000 +$800,000 +1.5% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $199,800,000 $51,700,000 -$2,300,000 -4.3% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $202,100,000 $48,400,000 -$5,100,000 -9.5% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $207,200,000 $46,500,000 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
Q3 2024 $53,200,000 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $54,000,000 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $53,500,000 +$14,700,000 +38% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q1 2023 $38,800,000 +$2,900,000 +8.1% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q1 2022 $35,900,000 +$7,100,000 +25% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q1 2021 $28,800,000 +$1,979,000 +7.4% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q1 2020 $26,821,000 -$319,000 -1.2% 01 Jan 2020 31 Mar 2020 10-Q 30 Apr 2021 2021 Q1
Q1 2019 $27,140,000 +$10,797,000 +66% 01 Jan 2019 31 Mar 2019 10-Q 01 May 2020 2020 Q1
Q1 2018 $16,343,000 +$1,493,000 +10% 01 Jan 2018 31 Mar 2018 10-Q 01 May 2019 2019 Q1
Q1 2017 $14,850,000 -$1,565,000 -9.5% 01 Jan 2017 31 Mar 2017 10-Q 27 Apr 2018 2018 Q1
Q1 2016 $16,415,000 +$52,000 +0.32% 01 Jan 2016 31 Mar 2016 10-Q 28 Apr 2017 2017 Q1
Q1 2015 $16,363,000 +$575,000 +3.6% 01 Jan 2015 31 Mar 2015 10-Q 03 May 2016 2016 Q1
Q1 2014 $15,788,000 +$5,097,000 +48% 01 Jan 2014 31 Mar 2014 10-Q 04 May 2015 2015 Q1
Q1 2013 $10,691,000 +$2,131,000 +25% 01 Jan 2013 31 Mar 2013 10-Q 05 May 2014 2014 Q1
Q1 2012 $8,560,000 -$298,000 -3.4% 01 Jan 2012 31 Mar 2012 10-Q 08 May 2013 2013 Q1
Q1 2011 $8,858,000 +$1,274,000 +17% 01 Jan 2011 31 Mar 2011 10-Q 10 May 2012 2012 Q1
Q1 2010 $7,584,000 01 Jan 2010 31 Mar 2010 10-Q 06 May 2011 2011 Q1

VERTEX PHARMACEUTICALS INC / MA Annual Depreciation, Depletion and Amortization (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $209,800,000 +$2,600,000 +1.3% 01 Jan 2025 31 Dec 2025 10-K 13 Feb 2026 2025 FY
2024 $207,200,000 +$25,900,000 +14% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
2023 $181,300,000 +$33,000,000 +22% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2026 2025 FY
2022 $148,300,000 +$22,700,000 +18% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $125,600,000 +$16,100,000 +15% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $109,500,000 +$2,600,000 +2.4% 01 Jan 2020 31 Dec 2020 10-K 10 Feb 2023 2022 FY
2019 $106,900,000 +$34,480,000 +48% 01 Jan 2019 31 Dec 2019 10-K 09 Feb 2022 2021 FY
2018 $72,420,000 +$11,023,000 +18% 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $61,397,000 -$1,000 -0% 01 Jan 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
2016 $61,398,000 -$945,000 -1.5% 01 Jan 2016 31 Dec 2016 10-K 13 Feb 2019 2018 FY
2015 $62,343,000 -$914,000 -1.4% 01 Jan 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
2014 $63,257,000 +$14,892,000 +31% 01 Jan 2014 31 Dec 2014 10-K 23 Feb 2017 2016 FY
2013 $48,365,000 +$10,174,000 +27% 01 Jan 2013 31 Dec 2013 10-K 16 Feb 2016 2015 FY
2012 $38,191,000 +$3,150,000 +9% 01 Jan 2012 31 Dec 2012 10-K 13 Feb 2015 2014 FY
2011 $35,041,000 +$4,582,000 +15% 01 Jan 2011 31 Dec 2011 10-K 11 Feb 2014 2013 FY
2010 $30,459,000 01 Jan 2010 31 Dec 2010 10-K 01 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.